KL-6 serum levels in adult cystic fibrosis patients Source: Annual Congress 2011 - Cystic fibrosis: clinical and laboratory studies Year: 2011
Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018
YKL-40 and KL-6 in serum and sputum samples of patients diagnosed with hypersensitivity pneumonitis. Source: International Congress 2019 – Environment, work and respiratory health in occupational and environmental lung diseases Year: 2019
Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020
CEA levels in the serum and induced sputum of lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005
Increased serum α1-antitrypsin level in COPD patients with predominant lung emphysema Source: Eur Respir J 2001; 18: Suppl. 33, 248s Year: 2001
Serum levels of TGFβ and VEGF in lung cancer patients and healthy subjects Source: Eur Respir J 2004; 24: Suppl. 48, 43s Year: 2004
Comparative study of CC16, KL-6 and SP-D as serum markers in sarcoid patients Source: Eur Respir J 2002; 20: Suppl. 38, 173s Year: 2002
Elevation of serum tumor markers in patients with interstitial lung disease Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011
Serum YKL-40 modulation in severe asthma patients treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
Serum levels of sFas and sFasL during chemotherapy of lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 329s Year: 2005
Serum KL-6, SP-D and MMP-2 as diagnostic biomarkers in asbestosis and silicosis Source: International Congress 2017 – Silicosis has not gone away Year: 2017
Serum CC16 is a potential predictor for IPF diagnosis and prognosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020
Serum neopterin and IL-6 as biomarkers in patients with COPD. Source: International Congress 2017 – Novel molecular and genetic targets in COPD Year: 2017
Serum markers of IPF Source: Research Seminar 2004 - Genotyping and Phenotyping of Diffuse Parenchymal Lung Diseases Year: 2004
KL-6 as a marker of alveolar inflammation in patients with ARDS Source: Eur Respir J 2006; 28: Suppl. 50, 635s Year: 2006
High level of serum SP-D with normal range of KL-6 predicts a good prognosis of patients with fibrotic changes on HRCT Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010
Serial change in serum KL-6 levels correlate with the pulmonary function variables in cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease and much more Year: 2010
High serum levels of YKL-40 in IPF Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology Year: 2008